EPRX Archives - BioTuesdays

Developments

Eupraxia reports new positive data from RESOLVE trial of EP-104GI in EoE

Eupraxia Pharmaceuticals (TSX:EPRX; NASDAQ:EPRX) announced positive clinical data from the fifth cohort of its RESOLVE Phase 1b/2a trial, a multi-center, open-label, dose-escalation study to evaluate the safety...

November 13, 2024

Developments

Lancet Rheumatology publishes Eupraxia’s Phase 2b data on EP-104IAR in knee OA

Eupraxia Pharmaceuticals (NASDAQ:EPRX; TSX:EPRX) has announced that the top-tier, peer-reviewed journal, Lancet Rheumatology, has published Phase 2b data from its SPRINGBOARD trial evaluating EP-104IAR for the treatment...

October 15, 2024

Executive Moves

Eupraxia expands Amanda Malone’s leadership role and names Rahul Sarugaser as EVP, corporate development

Eupraxia Pharmaceuticals (TSX:EPRX; NASDAQ:EPRX) has announced the appointments of Amanda Malone as chief operating and scientific officer and Rahul Sarugaser as executive vice president of corporate development. In her...

October 3, 2024

Markets

Raymond James ups Eupraxia PT on new osteoarthritis data

Raymond James raised its price target for Eupraxia Pharmaceuticals (TSX:EPRX) to $17 (Canadian) from $11, maintaining a “strong buy” rating, after the company reported positive Phase 2b data with EP-104IAR for pain...

June 27, 2023

Markets

RC ups PT; RJ reiterates ‘strong buy’, for Eupraxia on Phase 2b osteoarthritis data

Research Capital raised its price target for Eupraxia Pharmaceuticals (TSX:EPRX) to $25 (Canadian) from $10.30 and maintained a “speculative buy” rating after the company reported positive results from its Phase 2b...

June 26, 2023

Markets

RJ ups Eupraxia to strong buy ahead of Phase 2 OA data

Raymond James upgraded Eupraxia Pharmaceuticals (TSX:EPRX) to “strong buy” from “outperform” and maintained its price target of $11 (Canadian). The stock was quoted at $6.99, up 15 cents at midday on May 18. Pointing to...

May 18, 2023

Markets

Research Capital starts Eupraxia at speculative buy; PT $10.30 (Canadian)

Research Capital launched coverage of Eupraxia Pharmaceuticals (TSX:EPRX) with a “speculative buy” rating and price target of $10.30 (Canadian). The stock closed at $3.69 on Jan. 6. Eupraxia’s lead product, EP...

January 9, 2023

Markets

Raymond James ups Eupraxia PT to $9 (Canadian) on Phase 2 EoE trial

Raymond James raised its price target for Eupraxia Pharmaceuticals (TSXV:EPRX) to $9 (Canadian) from $7 and reiterated its “outperform” rating after the company initiated a Phase 2 clinical trial in eosinophilic...

October 31, 2022

Feature

Eupraxia Pharmaceutical’s novel release technology aims to improve lives of knee OA sufferers

Eupraxia Pharmaceuticals (TSX:EPRX) is developing a unique diffusion-based polymer-particle technology initially to provide knee osteoarthritis (OA) patients with an injection in the knee for an extended release of drug...

July 26, 2022

Developments

Eupraxia Pharma receives emerging life sciences award for 2022 in B.C.

Eupraxia Pharmaceuticals (TSX:EPRX) received the Emerging Life Sciences Company Award of the year from Life Sciences British Columbia. In a statement, Dr. James Helliwell, CEO of Eupraxia, said that following a...

July 9, 2022

Tag - EPRX

Eupraxia reports new positive data from RESOLVE trial of EP-104GI in EoE

Lancet Rheumatology publishes Eupraxia’s Phase 2b data on EP-104IAR in knee OA

Eupraxia expands Amanda Malone’s leadership role and names Rahul Sarugaser as EVP, corporate development

Raymond James ups Eupraxia PT on new osteoarthritis data

RC ups PT; RJ reiterates ‘strong buy’, for Eupraxia on Phase 2b osteoarthritis data

RJ ups Eupraxia to strong buy ahead of Phase 2 OA data

Research Capital starts Eupraxia at speculative buy; PT $10.30 (Canadian)

Raymond James ups Eupraxia PT to $9 (Canadian) on Phase 2 EoE trial

Eupraxia Pharmaceutical’s novel release technology aims to improve lives of knee OA sufferers

Eupraxia Pharma receives emerging life sciences award for 2022 in B.C.

General

More